EC approves Xtandi™ for third prostate cancer indication
SHARES
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
The European Commission (EC) has approved Astellas Pharma’s oral once-daily therapy Xtandi™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC), a cancer with a median survival of approximately three to four years. Enzalutamide is an androgen receptor signalling inhibitor.
With the new indication, enzalutamide is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer: non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC.
Share this article
Share this article
TOKYO, May 4, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) announced today that the European Commission (EC) has approved an additional indication for the oral once-daily therapy XTANDI™ (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). Men diagnosed with mHSPC tend to have a poor prognosis, with a median survival of approximately 3-4 years,
1 underscoring the need for new treatment options.
With this indication, enzalutamide is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC.
Astellas XTANDI™ (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Steven Francis Techet Steven Francis Techet
Steven Francis Techet was the consummate story teller. He probably should have written his own obituary, but here we are writing it for him, after his two-year battle with melanoma. Steven passed away peacefully on Saturday night, April 10, 2021, at Transitions LifeCare in Raleigh, N.C.
Steven was a devoted husband, loving father and doting grandfather. He is survived by his wife, Joan Richards Techet; his two children, Alexandra and Andrew Techet; his seven grandchildren; and his sister, Whitney Posillico.
Steven was born Aug. 15, 1945, in Manhattan, N.Y. He grew up in Garden City, N.Y., and was a graduate of Franklin and Marshall College and Washington University Law School in St. Louis, Mo.